CETP Inhibitors

Definition

Cholesteryl ester transfer protein (CETP) inhibitors block the plasma protein that mediates exchange of cholesteryl esters from HDL to VLDL/LDL particles. Inhibition raises HDL-C and — depending on the agent's selectivity — also lowers LDL-C and Lp(a) via redistribution of cholesteryl esters back to HDL. The drug class has had a turbulent development history, but obicetrapib (a next-generation hydrophilic, highly selective agent) is the most advanced surviving candidate after multiple predecessor failures.

Key Concepts

Mechanism of Action

• CETP shuttles cholesteryl esters from HDL to ApoB-containing lipoproteins (LDL, VLDL); inhibition reverses this flux, raising HDL-C and lowering LDL-C and non-HDL-C sources/obicetrapib-broadway-nejm-2025 (high)
• Genomic analyses confirm that naturally low CETP levels correlate with lower LDL-C and ApoB — not merely with higher HDL-C — supporting the LDL-lowering pathway as the cardiovascular benefit mechanism sources/obicetrapib-broadway-nejm-2025 (high)
• CETP inhibitors also lower Lp(a) — by redirecting apolipoprotein B–containing particles — in contrast to statins, which can modestly raise Lp(a) sources/obicetrapib-broadway-nejm-2025 (high)

Class History and Predecessor Failures

• Torcetrapib (Pfizer): First-in-class CETP inhibitor; Phase 3 ILLUMINATE trial terminated early due to 60% increase in CV mortality. Off-target aldosterone stimulation, blood pressure elevation, and electrolyte abnormalities drove harm — unrelated to CETP mechanism itself sources/obicetrapib-broadway-nejm-2025 (high)
• Dalcetrapib (Roche): Modest CETP inhibitor with minimal LDL-C–lowering effect; dal-OUTCOMES trial (n>15,000) terminated for futility — 0% CV event reduction; pure HDL-C raising without LDL-C lowering was insufficient for CV benefit sources/obicetrapib-broadway-nejm-2025 (high)
• Evacetrapib (Eli Lilly): Potent CETP inhibitor but ACCELERATE trial (n=12,093; 26-month follow-up) terminated for futility; treatment duration may have been inadequate relative to the degree of LDL-C reduction achieved sources/obicetrapib-broadway-nejm-2025 (high)
• Anacetrapib (Merck): Most potent CETP inhibitor studied at scale; REVEAL trial (n=30,449; median 4.1 years): 9% reduction in major coronary events; benefit attributed to non-HDL-C/LDL-C lowering (not HDL-C raising); not developed further due to prolonged tissue accumulation in adipose tissue sources/obicetrapib-broadway-nejm-2025 (high)

Obicetrapib — Pharmacology

• Highly selective, hydrophilic CETP inhibitor with avid binding to the CETP tunnel due to its physicochemical properties sources/obicetrapib-broadway-nejm-2025 (high)
• Hydrophilicity is key: Unlike anacetrapib (lipophilic), obicetrapib does NOT accumulate in adipose tissue — removing the long tissue half-life concern sources/obicetrapib-broadway-nejm-2025 (high)
• Oral administration; 10 mg once daily; suitable for combination with statins, ezetimibe, PCSK9 inhibitors

BROADWAY Trial — Key Results

Design: Multinational phase 3 RCT (n=2,530; 188 sites; China/Europe/Japan/US); HeFH or established ASCVD on maximum tolerated lipid-lowering therapy; obicetrapib 10 mg OD vs placebo for 365 days; 2:1 randomisation; primary endpoint: percent LDL-C change at day 84 sources/obicetrapib-broadway-nejm-2025 (high)

Lipid Effects at Day 84:

• Absolute LDL-C achieved: 62.8 mg/dL (obicetrapib) vs 92.3 mg/dL (placebo) from mean baseline 98 mg/dL
• Target attainment at day 84: <55 mg/dL in 51.0% vs 8.0%; <70 mg/dL in 68.4% vs 27.5%
• LDL-C reduction diminished by Day 365 (−24.0 pp), partly attributable to 11.5% premature discontinuation sources/obicetrapib-broadway-nejm-2025 (high)

Safety in BROADWAY:

• Adverse events comparable to placebo (59.7% vs 60.8%)
• New-onset diabetes/worsening glycaemia: 35.1% vs 40.0% (numerically favoured obicetrapib — contrast with torcetrapib off-target effects)
• No aldosterone changes, no blood pressure increase
• Exploratory CV events (not powered): HR 0.79 (95% CI 0.54–1.15) sources/obicetrapib-broadway-nejm-2025 (high)

Cardiovascular Outcomes Trial

• BROOKLYN trial (NCT05202509): Large, long-term outcomes trial of obicetrapib; results awaited; will determine if the lipid benefits translate to reduced MACE sources/obicetrapib-broadway-nejm-2025 (high)

Place in Therapy — Emerging Positioning

• Obicetrapib's ~30% additional LDL-C reduction on top of maximum statin ± ezetimibe occupies a space between ezetimibe (~18% additional reduction) and PCSK9 inhibitors (~45–64%) as an oral option
• Particularly relevant for patients who cannot or will not use injectable PCSK9 inhibitors (cost, access, needle aversion)
• The simultaneous Lp(a) lowering (−33.5%) distinguishes obicetrapib from statins and ezetimibe, which do not lower (and may raise) Lp(a) sources/obicetrapib-broadway-nejm-2025 (high)
• BROADWAY enrolled only 4% on PCSK9 inhibitors; incremental benefit on top of triple lipid-lowering therapy not yet characterised

Contradictions / Open Questions

• No CV outcomes data yet: BROADWAY is a lipid surrogate endpoint trial only; whether a 30% add-on LDL-C reduction translates to MACE reduction requires BROOKLYN results. Anacetrapib's REVEAL showed a 9% MACE reduction with a comparable degree of LDL-C lowering — obicetrapib should achieve at least similar benefit if the mechanism holds sources/obicetrapib-broadway-nejm-2025 (high)
• LDL-C effect diminishes at 1 year: The between-group difference declined from −36.6 pp (Day 30) to −24.0 pp (Day 365). This partially reflects discontinuations (11.5% dropout rate) but raises questions about whether LDL-C lowering is pharmacologically attenuated over time or whether compliance drives the difference — important for long-term outcomes projections
• High HDL-C elevation clinical relevance: HDL-C rose by +136.3 pp. Prior CETP inhibitor experience shows HDL-C raising has not translated to CV benefit (dalcetrapib, ILLUMINATE); the clinical significance of obicetrapib's HDL-C elevation remains uncertain and is not expected to drive outcomes independent of LDL-C lowering
• Lp(a) lowering causality: Obicetrapib lowers Lp(a) by ~33.5%, but patients were not selected for elevated Lp(a); the clinical significance of this Lp(a) reduction in patients with high baseline Lp(a) has not been characterised
• Comparison with injectable PCSK9 inhibitors: PCSK9 mAbs achieve 45–64% LDL-C reduction vs 30% with obicetrapib monotherapy; however PCSK9 mAbs have only 15–30% Lp(a) lowering vs 33.5% with obicetrapib — the two agents have complementary lipid profiles; head-to-head data are absent

Connections

• Related to concepts/Dyslipidemia-Management — obicetrapib as emerging oral nonstatin LDL-C–lowering agent
• Related to concepts/Familial-Hypercholesterolemia — HeFH patients enrolled in BROADWAY; oral add-on option when injectable agents not feasible
• Related to concepts/Lipoprotein-a — obicetrapib lowers Lp(a) by 33.5%; contrasts with statins (may raise Lp(a))
• Related to concepts/ASCVD-Risk-Assessment — treatment gap between statin and PCSK9 inhibitor use in secondary prevention

Sources

• sources/obicetrapib-broadway-nejm-2025